1887

Abstract

Oncolytic virus (OV) therapy is an emerging anti-cancer approach that utilizes viruses to preferentially infect and kill cancer cells, while not harming healthy cells. Vesicular stomatitis virus (VSV) is a prototypic non-segmented, negative-strand RNA virus with inherent OV qualities. Antiviral responses induced by type I interferon pathways are believed to be impaired in most cancer cells, making them more susceptible to VSV than normal cells. Several other factors make VSV a promising OV candidate for clinical use, including its well-studied biology, a small, easily manipulated genome, relative independence of a receptor or cell cycle, cytoplasmic replication without risk of host-cell transformation, and lack of pre-existing immunity in humans. Moreover, various VSV-based recombinant viruses have been engineered via reverse genetics to improve oncoselectivity, safety, oncotoxicity and stimulation of tumour-specific immunity. Alternative delivery methods are also being studied to minimize premature immune clearance of VSV. OV treatment as a monotherapy is being explored, although many studies have employed VSV in combination with radiotherapy, chemotherapy or other OVs. Preclinical studies with various cancers have demonstrated that VSV is a promising OV; as a result, a human clinical trial using VSV is currently in progress.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.046672-0
2012-12-01
2019-12-05
Loading full text...

Full text loading...

/deliver/fulltext/jgv/93/12/2529.html?itemId=/content/journal/jgv/10.1099/vir.0.046672-0&mimeType=html&fmt=ahah

References

  1. Alain T. , Lun X. , Martineau Y. , Sean P. , Pulendran B. , Petroulakis E. , Zemp F. J. , Lemay C. G. , Roy D. . & other authors ( 2010; ). Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. . Proc Natl Acad Sci U S A 107:, 1576–1581. [CrossRef] [PubMed]
    [Google Scholar]
  2. Altomonte J. , Braren R. , Schulz S. , Marozin S. , Rummeny E. J. , Schmid R. M. , Ebert O. . ( 2008a; ). Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats. . Hepatology 48:, 1864–1873. [CrossRef] [PubMed]
    [Google Scholar]
  3. Altomonte J. , Wu L. , Chen L. , Meseck M. , Ebert O. , García-Sastre A. , Fallon J. , Woo S. L. . ( 2008b; ). Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo . . Mol Ther 16:, 146–153. [CrossRef] [PubMed]
    [Google Scholar]
  4. Altomonte J. , Wu L. , Meseck M. , Chen L. , Ebert O. , Garcia-Sastre A. , Fallon J. , Mandeli J. , Woo S. L. . ( 2009; ). Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells. . Cancer Gene Ther 16:, 266–278.[PubMed]
    [Google Scholar]
  5. Ausubel L. J. , Meseck M. , Derecho I. , Lopez P. , Knoblauch C. , McMahon R. , Anderson J. , Dunphy N. , Quezada V. . & other authors ( 2011; ). Current good manufacturing practice production of an oncolytic recombinant vesicular stomatitis viral vector for cancer treatment. . Hum Gene Ther 22:, 489–497. [CrossRef] [PubMed]
    [Google Scholar]
  6. Ayala-Breton C. , Barber G. N. , Russell S. J. , Peng K. W. . ( 2012; ). Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins. . Hum Gene Ther 23:, 484–491. [CrossRef] [PubMed]
    [Google Scholar]
  7. Balachandran S. , Barber G. N. . ( 2004; ). Defective translational control facilitates vesicular stomatitis virus oncolysis. . Cancer Cell 5:, 51–65. [CrossRef] [PubMed]
    [Google Scholar]
  8. Balachandran S. , Barber G. N. . ( 2007; ). PKR in innate immunity, cancer, and viral oncolysis. . Methods Mol Biol 383:, 277–301.[PubMed]
    [Google Scholar]
  9. Ball L. A. , Pringle C. R. , Flanagan B. , Perepelitsa V. P. , Wertz G. W. . ( 1999; ). Phenotypic consequences of rearranging the P, M, and G genes of vesicular stomatitis virus. . J Virol 73:, 4705–4712.[PubMed]
    [Google Scholar]
  10. Barber G. N. . ( 2004; ). Vesicular stomatitis virus as an oncolytic vector. . Viral Immunol 17:, 516–527. [CrossRef] [PubMed]
    [Google Scholar]
  11. Barber G. N. . ( 2005; ). VSV-tumor selective replication and protein translation. . Oncogene 24:, 7710–7719. [CrossRef] [PubMed]
    [Google Scholar]
  12. Bergman I. , Griffin J. A. , Gao Y. , Whitaker-Dowling P. . ( 2007; ). Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu. . Int J Cancer 121:, 425–430. [CrossRef] [PubMed]
    [Google Scholar]
  13. Bi Z. , Barna M. , Komatsu T. , Reiss C. S. . ( 1995; ). Vesicular stomatitis virus infection of the central nervous system activates both innate and acquired immunity. . J Virol 69:, 6466–6472.[PubMed]
    [Google Scholar]
  14. Black B. L. , Rhodes R. B. , McKenzie M. , Lyles D. S. . ( 1993; ). The role of vesicular stomatitis virus matrix protein in inhibition of host-directed gene expression is genetically separable from its function in virus assembly. . J Virol 67:, 4814–4821.[PubMed]
    [Google Scholar]
  15. Boudreau J. E. , Bridle B. W. , Stephenson K. B. , Jenkins K. M. , Brunellière J. , Bramson J. L. , Lichty B. D. , Wan Y. . ( 2009; ). Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. . Mol Ther 17:, 1465–1472. [CrossRef] [PubMed]
    [Google Scholar]
  16. Breitbach C. J. , De Silva N. S. , Falls T. J. , Aladl U. , Evgin L. , Paterson J. , Sun Y. Y. , Roy D. G. , Rintoul J. L. . & other authors ( 2011; ). Targeting tumor vasculature with an oncolytic virus. . Mol Ther 19:, 886–894. [CrossRef] [PubMed]
    [Google Scholar]
  17. Bridle B. W. , Stephenson K. B. , Boudreau J. E. , Koshy S. , Kazdhan N. , Pullenayegum E. , Brunellière J. , Bramson J. L. , Lichty B. D. , Wan Y. . ( 2010; ). Potentiating cancer immunotherapy using an oncolytic virus. . Mol Ther 18:, 1430–1439. [CrossRef] [PubMed]
    [Google Scholar]
  18. Brown C. W. , Stephenson K. B. , Hanson S. , Kucharczyk M. , Duncan R. , Bell J. C. , Lichty B. D. . ( 2009; ). The p14 FAST protein of reptilian reovirus increases vesicular stomatitis virus neuropathogenesis. . J Virol 83:, 552–561. [CrossRef] [PubMed]
    [Google Scholar]
  19. Cary Z. D. , Willingham M. C. , Lyles D. S. . ( 2011; ). Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo . . J Virol 85:, 5708–5717. [CrossRef] [PubMed]
    [Google Scholar]
  20. Chakraborty P. , Seemann J. , Mishra R. K. , Wei J. H. , Weil L. , Nussenzveig D. R. , Heiber J. , Barber G. N. , Dasso M. , Fontoura B. M. . ( 2009; ). Vesicular stomatitis virus inhibits mitotic progression and triggers cell death. . EMBO Rep 10:, 1154–1160. [CrossRef] [PubMed]
    [Google Scholar]
  21. Chang G. , Xu S. , Watanabe M. , Jayakar H. R. , Whitt M. A. , Gingrich J. R. . ( 2010; ). Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer. . J Urol 183:, 1611–1618. [CrossRef] [PubMed]
    [Google Scholar]
  22. Chauhan V. S. , Furr S. R. , Sterka D. G. Jr , Nelson D. A. , Moerdyk-Schauwecker M. , Marriott I. , Grdzelishvili V. Z. . ( 2010; ). Vesicular stomatitis virus infects resident cells of the central nervous system and induces replication-dependent inflammatory responses. . Virology 400:, 187–196. [CrossRef] [PubMed]
    [Google Scholar]
  23. Chelbi-Alix M. K. , Quignon F. , Pelicano L. , Koken M. H. , de Thé H. . ( 1998; ). Resistance to virus infection conferred by the interferon-induced promyelocytic leukemia protein. . J Virol 72:, 1043–1051.[PubMed]
    [Google Scholar]
  24. Connor J. H. , Lyles D. S. . ( 2002; ). Vesicular stomatitis virus infection alters the eIF4F translation initiation complex and causes dephosphorylation of the eIF4E binding protein 4E-BP1. . J Virol 76:, 10177–10187. [CrossRef] [PubMed]
    [Google Scholar]
  25. Coulon P. , Deutsch V. , Lafay F. , Martinet-Edelist C. , Wyers F. , Herman R. C. , Flamand A. . ( 1990; ). Genetic evidence for multiple functions of the matrix protein of vesicular stomatitis virus. . J Gen Virol 71:, 991–996. [CrossRef] [PubMed]
    [Google Scholar]
  26. Cripe T. P. , Wang P. Y. , Marcato P. , Mahller Y. Y. , Lee P. W. . ( 2009; ). Targeting cancer-initiating cells with oncolytic viruses. . Mol Ther 17:, 1677–1682. [CrossRef] [PubMed]
    [Google Scholar]
  27. Cureton D. K. , Massol R. H. , Whelan S. P. , Kirchhausen T. . ( 2010; ). The length of vesicular stomatitis virus particles dictates a need for actin assembly during clathrin-dependent endocytosis. . PLoS Pathog 6:, e1001127. [CrossRef] [PubMed]
    [Google Scholar]
  28. Dal Canto M. C. , Rabinowitz S. G. , Johnson T. C. . ( 1976; ). Status spongiosus resulting from intracerebral infection of mice with temperature-sensitive mutants of vesicular stomatitis virus. . Br J Exp Pathol 57:, 321–330.[PubMed]
    [Google Scholar]
  29. Dalton K. P. , Rose J. K. . ( 2001; ). Vesicular stomatitis virus glycoprotein containing the entire green fluorescent protein on its cytoplasmic domain is incorporated efficiently into virus particles. . Virology 279:, 414–421. [CrossRef] [PubMed]
    [Google Scholar]
  30. Diallo J. S. , Vähä-Koskela M. , Le Boeuf F. , Bell J. . ( 2012; ). Propagation, purification, and in vivo testing of oncolytic vesicular stomatitis virus strains. . Methods Mol Biol 797:, 127–140. [CrossRef] [PubMed]
    [Google Scholar]
  31. Diaz R. M. , Galivo F. , Kottke T. , Wongthida P. , Qiao J. , Thompson J. , Valdes M. , Barber G. , Vile R. G. . ( 2007; ). Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. . Cancer Res 67:, 2840–2848. [CrossRef] [PubMed]
    [Google Scholar]
  32. Dinh P. X. , Beura L. K. , Panda D. , Das A. , Pattnaik A. K. . ( 2011; ). Antagonistic effects of cellular poly(C) binding proteins on vesicular stomatitis virus gene expression. . J Virol 85:, 9459–9471. [CrossRef] [PubMed]
    [Google Scholar]
  33. Drolet B. S. , Stuart M. A. , Derner J. D. . ( 2009; ). Infection of Melanoplus sanguinipes grasshoppers following ingestion of rangeland plant species harboring vesicular stomatitis virus. . Appl Environ Microbiol 75:, 3029–3033. [CrossRef] [PubMed]
    [Google Scholar]
  34. Ebert O. , Shinozaki K. , Kournioti C. , Park M. S. , García-Sastre A. , Woo S. L. . ( 2004; ). Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. . Cancer Res 64:, 3265–3270. [CrossRef] [PubMed]
    [Google Scholar]
  35. Edge R. E. , Falls T. J. , Brown C. W. , Lichty B. D. , Atkins H. , Bell J. C. . ( 2008; ). A let-7 microRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. . Mol Ther 16:, 1437–1443. [CrossRef] [PubMed]
    [Google Scholar]
  36. Egan M. A. , Chong S. Y. , Rose N. F. , Megati S. , Lopez K. J. , Schadeck E. B. , Johnson J. E. , Masood A. , Piacente P. . & other authors ( 2004; ). Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. . AIDS Res Hum Retroviruses 20:, 989–1004. [CrossRef] [PubMed]
    [Google Scholar]
  37. Faria P. A. , Chakraborty P. , Levay A. , Barber G. N. , Ezelle H. J. , Enninga J. , Arana C. , van Deursen J. , Fontoura B. M. . ( 2005; ). VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway. . Mol Cell 17:, 93–102. [CrossRef] [PubMed]
    [Google Scholar]
  38. Fernandez M. , Porosnicu M. , Markovic D. , Barber G. N. . ( 2002; ). Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. . J Virol 76:, 895–904. [CrossRef] [PubMed]
    [Google Scholar]
  39. Finke S. , Conzelmann K. K. . ( 2005; ). Recombinant rhabdoviruses: vectors for vaccine development and gene therapy. . Curr Top Microbiol Immunol 292:, 165–200. [CrossRef] [PubMed]
    [Google Scholar]
  40. Flanagan E. B. , Zamparo J. M. , Ball L. A. , Rodriguez L. L. , Wertz G. W. . ( 2001; ). Rearrangement of the genes of vesicular stomatitis virus eliminates clinical disease in the natural host: new strategy for vaccine development. . J Virol 75:, 6107–6114. [CrossRef] [PubMed]
    [Google Scholar]
  41. Frei K. , Malipiero U. V. , Leist T. P. , Zinkernagel R. M. , Schwab M. E. , Fontana A. . ( 1989; ). On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases. . Eur J Immunol 19:, 689–694. [CrossRef] [PubMed]
    [Google Scholar]
  42. Friedman G. K. , Cassady K. A. , Beierle E. A. , Markert J. M. , Gillespie G. Y. . ( 2012; ). Targeting pediatric cancer stem cells with oncolytic virotherapy. . Pediatr Res 71:, 500–510. [CrossRef] [PubMed]
    [Google Scholar]
  43. Furr S. R. , Chauhan V. S. , Sterka D. Jr , Grdzelishvili V. Z. , Marriott I. . ( 2008; ). Characterization of retinoic acid-inducible gene-I expression in primary murine glia following exposure to vesicular stomatitis virus. . J Neurovirol 14:, 503–513.[PubMed] [CrossRef]
    [Google Scholar]
  44. Furr S. R. , Moerdyk-Schauwecker M. , Grdzelishvili V. Z. , Marriott I. . ( 2010; ). RIG-I mediates nonsegmented negative-sense RNA virus-induced inflammatory immune responses of primary human astrocytes. . Glia 58:, 1620–1629.[PubMed]
    [Google Scholar]
  45. Gaddy D. F. , Lyles D. S. . ( 2005; ). Vesicular stomatitis viruses expressing wild-type or mutant M proteins activate apoptosis through distinct pathways. . J Virol 79:, 4170–4179. [CrossRef] [PubMed]
    [Google Scholar]
  46. Gaddy D. F. , Lyles D. S. . ( 2007; ). Oncolytic vesicular stomatitis virus induces apoptosis via signaling through PKR, Fas, and Daxx. . J Virol 81:, 2792–2804. [CrossRef] [PubMed]
    [Google Scholar]
  47. Galivo F. , Diaz R. M. , Thanarajasingam U. , Jevremovic D. , Wongthida P. , Thompson J. , Kottke T. , Barber G. N. , Melcher A. , Vile R. G. . ( 2010; ). Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. . Hum Gene Ther 21:, 439–450. [CrossRef] [PubMed]
    [Google Scholar]
  48. Gao Y. , Whitaker-Dowling P. , Watkins S. C. , Griffin J. A. , Bergman I. . ( 2006; ). Rapid adaptation of a recombinant vesicular stomatitis virus to a targeted cell line. . J Virol 80:, 8603–8612. [CrossRef] [PubMed]
    [Google Scholar]
  49. Garber K. . ( 2006; ). China approves world’s first oncolytic virus therapy for cancer treatment. . J Natl Cancer Inst 98:, 298–300. [CrossRef] [PubMed]
    [Google Scholar]
  50. Ge P. , Tsao J. , Schein S. , Green T. J. , Luo M. , Zhou Z. H. . ( 2010; ). Cryo-EM model of the bullet-shaped vesicular stomatitis virus. . Science 327:, 689–693. [CrossRef] [PubMed]
    [Google Scholar]
  51. Georgel P. , Jiang Z. , Kunz S. , Janssen E. , Mols J. , Hoebe K. , Bahram S. , Oldstone M. B. , Beutler B. . ( 2007; ). Vesicular stomatitis virus glycoprotein G activates a specific antiviral Toll-like receptor 4-dependent pathway. . Virology 362:, 304–313. [CrossRef] [PubMed]
    [Google Scholar]
  52. Ghiringhelli F. , Menard C. , Puig P. E. , Ladoire S. , Roux S. , Martin F. , Solary E. , Le Cesne A. , Zitvogel L. , Chauffert B. . ( 2007; ). Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. . Cancer Immunol Immunother 56:, 641–648. [CrossRef] [PubMed]
    [Google Scholar]
  53. Goel A. , Carlson S. K. , Classic K. L. , Greiner S. , Naik S. , Power A. T. , Bell J. C. , Russell S. J. . ( 2007; ). Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Δ51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. . Blood 110:, 2342–2350. [CrossRef] [PubMed]
    [Google Scholar]
  54. Hamacher R. , Schmid R. M. , Saur D. , Schneider G. . ( 2008; ). Apoptotic pathways in pancreatic ductal adenocarcinoma. . Mol Cancer 7:, 64. [CrossRef] [PubMed]
    [Google Scholar]
  55. Hammill A. M. , Conner J. , Cripe T. P. . ( 2010; ). Oncolytic virotherapy reaches adolescence. . Pediatr Blood Cancer 55:, 1253–1263. [CrossRef] [PubMed]
    [Google Scholar]
  56. Hanahan D. , Weinberg R. A. . ( 2011; ). Hallmarks of cancer: the next generation. . Cell 144:, 646–674. [CrossRef] [PubMed]
    [Google Scholar]
  57. Hansen D. E. , Thurmond M. C. , Thorburn M. . ( 1985; ). Factors associated with the spread of clinical vesicular stomatitis in California dairy cattle. . Am J Vet Res 46:, 789–795.[PubMed]
    [Google Scholar]
  58. Harashima A. , Guettouche T. , Barber G. N. . ( 2010; ). Phosphorylation of the NFAR proteins by the dsRNA-dependent protein kinase PKR constitutes a novel mechanism of translational regulation and cellular defense. . Genes Dev 24:, 2640–2653. [CrossRef] [PubMed]
    [Google Scholar]
  59. Heiber J. F. , Barber G. N. . ( 2011; ). Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent. . J Virol 85:, 10440–10450. [CrossRef] [PubMed]
    [Google Scholar]
  60. Heinrich B. S. , Cureton D. K. , Rahmeh A. A. , Whelan S. P. . ( 2010; ). Protein expression redirects vesicular stomatitis virus RNA synthesis to cytoplasmic inclusions. . PLoS Pathog 6:, e1000958. [CrossRef] [PubMed]
    [Google Scholar]
  61. Hoffmann M. , Wu Y. J. , Gerber M. , Berger-Rentsch M. , Heimrich B. , Schwemmle M. , Zimmer G. . ( 2010; ). Fusion-active glycoprotein G mediates the cytotoxicity of vesicular stomatitis virus M mutants lacking host shut-off activity. . J Gen Virol 91:, 2782–2793. [CrossRef] [PubMed]
    [Google Scholar]
  62. Hornung V. , Ellegast J. , Kim S. , Brzózka K. , Jung A. , Kato H. , Poeck H. , Akira S. , Conzelmann K. K. . & other authors ( 2006; ). 5′-Triphosphate RNA is the ligand for RIG-I. . Science 314:, 994–997. [CrossRef] [PubMed]
    [Google Scholar]
  63. Huneycutt B. S. , Bi Z. , Aoki C. J. , Reiss C. S. . ( 1993; ). Central neuropathogenesis of vesicular stomatitis virus infection of immunodeficient mice. . J Virol 67:, 6698–6706.[PubMed]
    [Google Scholar]
  64. Ikeda K. , Wakimoto H. , Ichikawa T. , Jhung S. , Hochberg F. H. , Louis D. N. , Chiocca E. A. . ( 2000; ). Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. . J Virol 74:, 4765–4775. [CrossRef] [PubMed]
    [Google Scholar]
  65. Irie T. , Carnero E. , Okumura A. , García-Sastre A. , Harty R. N. . ( 2007; ). Modifications of the PSAP region of the matrix protein lead to attenuation of vesicular stomatitis virus in vitro and in vivo . . J Gen Virol 88:, 2559–2567. [CrossRef] [PubMed]
    [Google Scholar]
  66. Janelle V. , Brassard F. , Lapierre P. , Lamarre A. , Poliquin L. . ( 2011; ). Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy. . J Virol 85:, 6513–6520. [CrossRef] [PubMed]
    [Google Scholar]
  67. Jenks N. , Myers R. , Greiner S. M. , Thompson J. , Mader E. K. , Greenslade A. , Griesmann G. E. , Federspiel M. J. , Rakela J. . & other authors ( 2010; ). Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-β in rodents and nonhuman primates. . Hum Gene Ther 21:, 451–462. [CrossRef] [PubMed]
    [Google Scholar]
  68. Jensen H. , Andresen L. , Nielsen J. , Christensen J. P. , Skov S. . ( 2011; ). Vesicular stomatitis virus infection promotes immune evasion by preventing NKG2D-ligand surface expression. . PLoS ONE 6:, e23023. [CrossRef] [PubMed]
    [Google Scholar]
  69. Johnson J. E. , Nasar F. , Coleman J. W. , Price R. E. , Javadian A. , Draper K. , Lee M. , Reilly P. A. , Clarke D. K. . & other authors ( 2007; ). Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. . Virology 360:, 36–49. [CrossRef] [PubMed]
    [Google Scholar]
  70. Kelly E. , Russell S. J. . ( 2007; ). History of oncolytic viruses: genesis to genetic engineering. . Mol Ther 15:, 651–659.[PubMed] [CrossRef]
    [Google Scholar]
  71. Kelly E. J. , Nace R. , Barber G. N. , Russell S. J. . ( 2010; ). Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting. . J Virol 84:, 1550–1562. [CrossRef] [PubMed]
    [Google Scholar]
  72. Kopecky S. A. , Willingham M. C. , Lyles D. S. . ( 2001; ). Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus. . J Virol 75:, 12169–12181. [CrossRef] [PubMed]
    [Google Scholar]
  73. Kottke T. , Diaz R. M. , Kaluza K. , Pulido J. , Galivo F. , Wongthida P. , Thompson J. , Willmon C. , Barber G. N. . & other authors ( 2008a; ). Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer. . Mol Ther 16:, 1910–1918. [CrossRef] [PubMed]
    [Google Scholar]
  74. Kottke T. , Galivo F. , Wongthida P. , Diaz R. M. , Thompson J. , Jevremovic D. , Barber G. N. , Hall G. , Chester J. . & other authors ( 2008b; ). Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. . Mol Ther 16:, 1217–1226. [CrossRef] [PubMed]
    [Google Scholar]
  75. Kottke T. , Hall G. , Pulido J. , Diaz R. M. , Thompson J. , Chong H. , Selby P. , Coffey M. , Pandha H. . & other authors ( 2010; ). Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. . J Clin Invest 120:, 1551–1560. [CrossRef] [PubMed]
    [Google Scholar]
  76. Krishnamoorthy J. , Mounir Z. , Raven J. F. , Koromilas A. E. . ( 2008; ). The eIF2α kinases inhibit vesicular stomatitis virus replication independently of eIF2alpha phosphorylation. . Cell Cycle 7:, 2346–2351.[PubMed] [CrossRef]
    [Google Scholar]
  77. Labib M. , Zamay A. S. , Muharemagic D. , Chechik A. , Bell J. C. , Berezovski M. V. . ( 2012; ). Electrochemical sensing of aptamer-facilitated virus immunoshielding. . Anal Chem 84:, 1677–1686. [CrossRef] [PubMed]
    [Google Scholar]
  78. Lawson N. D. , Stillman E. A. , Whitt M. A. , Rose J. K. . ( 1995; ). Recombinant vesicular stomatitis viruses from DNA. . Proc Natl Acad Sci U S A 92:, 4477–4481. [CrossRef] [PubMed]
    [Google Scholar]
  79. Le Boeuf F. , Diallo J. S. , McCart J. A. , Thorne S. , Falls T. , Stanford M. , Kanji F. , Auer R. , Brown C. W. . & other authors ( 2010; ). Synergistic interaction between oncolytic viruses augments tumor killing. . Mol Ther 18:, 888–895. [CrossRef] [PubMed]
    [Google Scholar]
  80. Le Boeuf F. , Niknejad N. , Wang J. , Auer R. , Weberpals J. I. , Bell J. C. , Dimitroulakos J. . ( 2012; ). Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection. . Int J Cancer 131:, E204–E215. [CrossRef] [PubMed]
    [Google Scholar]
  81. Leveille S. , Goulet M. L. , Lichty B. D. , Hiscott J. . ( 2011a; ). Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation. . J Virol 85:, 12160–12169. [CrossRef] [PubMed]
    [Google Scholar]
  82. Leveille S. , Samuel S. , Goulet M. L. , Hiscott J. . ( 2011b; ). Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy. . Cancer Gene Ther 18:, 435–443. [CrossRef] [PubMed]
    [Google Scholar]
  83. Li Q. , Tainsky M. A. . ( 2011; ). Epigenetic silencing of IRF7 and/or IRF5 in lung cancer cells leads to increased sensitivity to oncolytic viruses. . PLoS ONE 6:, e28683. [CrossRef] [PubMed]
    [Google Scholar]
  84. Lichty B. D. , Power A. T. , Stojdl D. F. , Bell J. C. . ( 2004; ). Vesicular stomatitis virus: re-inventing the bullet. . Trends Mol Med 10:, 210–216. [CrossRef] [PubMed]
    [Google Scholar]
  85. Linge C. , Gewert D. , Rossmann C. , Bishop J. A. , Crowe J. S. . ( 1995; ). Interferon system defects in human malignant melanoma. . Cancer Res 55:, 4099–4104.[PubMed]
    [Google Scholar]
  86. Lyles D. S. , Rupprecht C. E. . ( 2007; ). Rhabdoviridae . . In Fields Virology, , 5th edn., pp. 1363–1408. Edited by Knipe D. M. , Howley P. M. . . Philadelphia, PA:: Lippincott Williams & Wilkins;.
    [Google Scholar]
  87. Marozin S. , Altomonte J. , Stadler F. , Thasler W. E. , Schmid R. M. , Ebert O. . ( 2008; ). Inhibition of the IFN-β response in hepatocellular carcinoma by alternative spliced isoform of IFN regulatory factor-3. . Mol Ther 16:, 1789–1797. [CrossRef] [PubMed]
    [Google Scholar]
  88. Marozin S. , De Toni E. N. , Rizzani A. , Altomonte J. , Junger A. , Schneider G. , Thasler W. E. , Kato N. , Schmid R. M. , Ebert O. . ( 2010; ). Cell cycle progression or translation control is not essential for vesicular stomatitis virus oncolysis of hepatocellular carcinoma. . PLoS ONE 5:, e10988. [CrossRef] [PubMed]
    [Google Scholar]
  89. Martinez I. , Rodriguez L. L. , Jimenez C. , Pauszek S. J. , Wertz G. W. . ( 2003; ). Vesicular stomatitis virus glycoprotein is a determinant of pathogenesis in swine, a natural host. . J Virol 77:, 8039–8047. [CrossRef] [PubMed]
    [Google Scholar]
  90. Matin S. F. , Rackley R. R. , Sadhukhan P. C. , Kim M. S. , Novick A. C. , Bandyopadhyay S. K. . ( 2001; ). Impaired α-interferon signaling in transitional cell carcinoma: lack of p48 expression in 5637 cells. . Cancer Res 61:, 2261–2266.[PubMed]
    [Google Scholar]
  91. Melcher A. , Parato K. , Rooney C. M. , Bell J. C. . ( 2011; ). Thunder and lightning: immunotherapy and oncolytic viruses collide. . Mol Ther 19:, 1008–1016. [CrossRef] [PubMed]
    [Google Scholar]
  92. Miller J. , Bidula S. M. , Jensen T. M. , Reiss C. S. . ( 2009; ). Cytokine-modified VSV is attenuated for neural pathology, but is both highly immunogenic and oncolytic. . Int J Infereron Cytokine Mediator Res 1:, 15–32.[PubMed]
    [Google Scholar]
  93. Miller J. M. , Bidula S. M. , Jensen T. M. , Reiss C. S. . ( 2010; ). Vesicular stomatitis virus modified with single chain IL-23 exhibits oncolytic activity against tumor cells in vitro and in vivo . . Int J Infereron Cytokine Mediator Res 2010:, 63–72.[PubMed]
    [Google Scholar]
  94. Mire C. E. , Whitt M. A. . ( 2011; ). The protease-sensitive loop of the vesicular stomatitis virus matrix protein is involved in virus assembly and protein translation. . Virology 416:, 16–25. [CrossRef] [PubMed]
    [Google Scholar]
  95. Moerdyk-Schauwecker M. , Destephanis D. , Hastie E. , Grdzelishvili V. Z. . ( 2011; ). Detecting protein–protein interactions in vesicular stomatitis virus using a cytoplasmic yeast two hybrid system. . J Virol Methods 173:, 203–212. [CrossRef] [PubMed]
    [Google Scholar]
  96. Moussavi M. , Fazli L. , Tearle H. , Guo Y. , Cox M. , Bell J. , Ong C. , Jia W. , Rennie P. S. . ( 2010; ). Oncolysis of prostate cancers induced by vesicular stomatitis virus in PTEN knockout mice. . Cancer Res 70:, 1367–1376. [CrossRef] [PubMed]
    [Google Scholar]
  97. Muik A. , Kneiske I. , Werbizki M. , Wilflingseder D. , Giroglou T. , Ebert O. , Kraft A. , Dietrich U. , Zimmer G. . & other authors ( 2011; ). Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism. . J Virol 85:, 5679–5684. [CrossRef] [PubMed]
    [Google Scholar]
  98. Muik A. , Dold C. , Geiß Y. , Volk A. , Werbizki M. , Dietrich U. , von Laer D. . ( 2012; ). Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy. . J Mol Med (Berl) 90:, 959–970. [CrossRef] [PubMed]
    [Google Scholar]
  99. Murphy A. M. , Besmer D. M. , Moerdyk-Schauwecker M. , Moestl N. , Ornelles D. A. , Mukherjee P. , Grdzelishvili V. Z. . ( 2012; ). Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. . J Virol 86:, 3073–3087. [CrossRef] [PubMed]
    [Google Scholar]
  100. Naik S. , Russell S. J. . ( 2009; ). Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. . Expert Opin Biol Ther 9:, 1163–1176. [CrossRef] [PubMed]
    [Google Scholar]
  101. Naik S. , Nace R. , Federspiel M. J. , Barber G. N. , Peng K. W. , Russell S. J. . ( 2012; ). Curative one-shot systemic virotherapy in murine myeloma. . Leukemia 26:, 1870–1878. [CrossRef] [PubMed]
    [Google Scholar]
  102. Nakashima H. , Kaur B. , Chiocca E. A. . ( 2010; ). Directing systemic oncolytic viral delivery to tumors via carrier cells. . Cytokine Growth Factor Rev 21:, 119–126. [CrossRef] [PubMed]
    [Google Scholar]
  103. Nguyên T. L. , Abdelbary H. , Arguello M. , Breitbach C. , Leveille S. , Diallo J. S. , Yasmeen A. , Bismar T. A. , Kirn D. . & other authors ( 2008; ). Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. . Proc Natl Acad Sci U S A 105:, 14981–14986. [CrossRef] [PubMed]
    [Google Scholar]
  104. Noser J. A. , Mael A. A. , Sakuma R. , Ohmine S. , Marcato P. , Lee P. W. , Ikeda Y. . ( 2007; ). The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells. . Mol Ther 15:, 1531–1536. [CrossRef] [PubMed]
    [Google Scholar]
  105. Obuchi M. , Fernandez M. , Barber G. N. . ( 2003; ). Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. . J Virol 77:, 8843–8856. [CrossRef] [PubMed]
    [Google Scholar]
  106. Oliere S. , Arguello M. , Mesplede T. , Tumilasci V. , Nakhaei P. , Stojdl D. , Sonenberg N. , Bell J. , Hiscott J. . ( 2008; ). Vesicular stomatitis virus oncolysis of T lymphocytes requires cell cycle entry and translation initiation. . J Virol 82:, 5735–5749. [CrossRef] [PubMed]
    [Google Scholar]
  107. Ozduman K. , Wollmann G. , Ahmadi S. A. , van den Pol A. N. . ( 2009; ). Peripheral immunization blocks lethal actions of vesicular stomatitis virus within the brain. . J Virol 83:, 11540–11549. [CrossRef] [PubMed]
    [Google Scholar]
  108. Pearson A. S. , Koch P. E. , Atkinson N. , Xiong M. , Finberg R. W. , Roth J. A. , Fang B. . ( 1999; ). Factors limiting adenovirus-mediated gene transfer into human lung and pancreatic cancer cell lines. . Clin Cancer Res 5:, 4208–4213.[PubMed]
    [Google Scholar]
  109. Peng K. W. , Myers R. , Greenslade A. , Mader E. , Greiner S. , Federspiel M. J. , Dispenzieri A. , Russell S. J. . ( 2012; ). Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses. . Gene Ther (in press). doi:10.1038/gt.2012.31 [CrossRef] [PubMed]
    [Google Scholar]
  110. Petersen J. M. , Her L. S. , Varvel V. , Lund E. , Dahlberg J. E. . ( 2000; ). The matrix protein of vesicular stomatitis virus inhibits nucleocytoplasmic transport when it is in the nucleus and associated with nuclear pore complexes. . Mol Cell Biol 20:, 8590–8601. [CrossRef] [PubMed]
    [Google Scholar]
  111. Pfeffer L. M. , Wang C. , Constantinescu S. N. , Croze E. , Blatt L. M. , Albino A. P. , Nanus D. M. . ( 1996; ). Human renal cancers resistant to IFN’s antiproliferative action exhibit sensitivity to IFN’s gene-inducing and antiviral actions. . J Urol 156:, 1867–1871. [CrossRef] [PubMed]
    [Google Scholar]
  112. Plakhov I. V. , Arlund E. E. , Aoki C. , Reiss C. S. . ( 1995; ). The earliest events in vesicular stomatitis virus infection of the murine olfactory neuroepithelium and entry of the central nervous system. . Virology 209:, 257–262. [CrossRef] [PubMed]
    [Google Scholar]
  113. Porosnicu M. , Mian A. , Barber G. N. . ( 2003; ). The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene. . Cancer Res 63:, 8366–8376.[PubMed]
    [Google Scholar]
  114. Power A. T. , Bell J. C. . ( 2007; ). Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. . Mol Ther 15:, 660–665.[PubMed] [CrossRef]
    [Google Scholar]
  115. Power A. T. , Bell J. C. . ( 2008; ). Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy. . Gene Ther 15:, 772–779. [CrossRef] [PubMed]
    [Google Scholar]
  116. Pulido J. , Kottke T. , Thompson J. , Galivo F. , Wongthida P. , Diaz R. M. , Rommelfanger D. , Ilett E. , Pease L. . & other authors ( 2012; ). Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. . Nat Biotechnol 30:, 337–343. [CrossRef] [PubMed]
    [Google Scholar]
  117. Qiao J. , Wang H. , Kottke T. , Diaz R. M. , Willmon C. , Hudacek A. , Thompson J. , Parato K. , Bell J. . & other authors ( 2008a; ). Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. . Gene Ther 15:, 604–616. [CrossRef] [PubMed]
    [Google Scholar]
  118. Qiao J. , Wang H. , Kottke T. , White C. , Twigger K. , Diaz R. M. , Thompson J. , Selby P. , de Bono J. . & other authors ( 2008b; ). Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. . Clin Cancer Res 14:, 259–269. [CrossRef] [PubMed]
    [Google Scholar]
  119. Quiroz E. , Moreno N. , Peralta P. H. , Tesh R. B. . ( 1988; ). A human case of encephalitis associated with vesicular stomatitis virus (Indiana serotype) infection. . Am J Trop Med Hyg 39:, 312–314.[PubMed]
    [Google Scholar]
  120. Reiss C. S. , Plakhov I. V. , Komatsu T. . ( 1998; ). Viral replication in olfactory receptor neurons and entry into the olfactory bulb and brain. . Ann N Y Acad Sci 855:, 751–761. [CrossRef] [PubMed]
    [Google Scholar]
  121. Rieder M. , Conzelmann K. K. . ( 2009; ). Rhabdovirus evasion of the interferon system. . J Interferon Cytokine Res 29:, 499–510. [CrossRef] [PubMed]
    [Google Scholar]
  122. Rose N. F. , Marx P. A. , Luckay A. , Nixon D. F. , Moretto W. J. , Donahoe S. M. , Montefiori D. , Roberts A. , Buonocore L. , Rose J. K. . ( 2001; ). An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. . Cell 106:, 539–549. [CrossRef] [PubMed]
    [Google Scholar]
  123. Saloura V. , Wang L. C. , Fridlender Z. G. , Sun J. , Cheng G. , Kapoor V. , Sterman D. H. , Harty R. N. , Okumura A. . & other authors ( 2010; ). Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. . Hum Gene Ther 21:, 51–64. [CrossRef] [PubMed]
    [Google Scholar]
  124. Samuel S. , Tumilasci V. F. , Oliere S. , Nguyên T. L. , Shamy A. , Bell J. , Hiscott J. . ( 2010; ). VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia. . Mol Ther 18:, 2094–2103. [CrossRef] [PubMed]
    [Google Scholar]
  125. Sarojini S. , Theofanis T. , Reiss C. S. . ( 2011; ). Interferon-induced tetherin restricts vesicular stomatitis virus release in neurons. . DNA Cell Biol 30:, 965–974. [CrossRef] [PubMed]
    [Google Scholar]
  126. Schache P. , Gürlevik E. , Strüver N. , Woller N. , Malek N. , Zender L. , Manns M. , Wirth T. , Kühnel F. , Kubicka S. . ( 2009; ). VSV virotherapy improves chemotherapy by triggering apoptosis due to proteasomal degradation of Mcl-1. . Gene Ther 16:, 849–861. [CrossRef] [PubMed]
    [Google Scholar]
  127. Schellekens H. , Smiers-de Vreede E. , de Reus A. , Dijkema R. . ( 1984; ). Antiviral activity of interferon in rats and the effect of immune suppression. . J Gen Virol 65:, 391–396. [CrossRef] [PubMed]
    [Google Scholar]
  128. Schnell M. J. , Buonocore L. , Kretzschmar E. , Johnson E. , Rose J. K. . ( 1996; ). Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. . Proc Natl Acad Sci U S A 93:, 11359–11365. [CrossRef] [PubMed]
    [Google Scholar]
  129. Sharif-Askari E. , Nakhaei P. , Oliere S. , Tumilasci V. , Hernandez E. , Wilkinson P. , Lin R. , Bell J. , Hiscott J. . ( 2007; ). Bax-dependent mitochondrial membrane permeabilization enhances IRF3-mediated innate immune response during VSV infection. . Virology 365:, 20–33. [CrossRef] [PubMed]
    [Google Scholar]
  130. Shi Z. , Cai Z. , Sanchez A. , Zhang T. , Wen S. , Wang J. , Yang J. , Fu S. , Zhang D. . ( 2011; ). A novel Toll-like receptor that recognizes vesicular stomatitis virus. . J Biol Chem 286:, 4517–4524. [CrossRef] [PubMed]
    [Google Scholar]
  131. Shin E. J. , Wanna G. B. , Choi B. , Aguila D. III , Ebert O. , Genden E. M. , Woo S. L. . ( 2007a; ). Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma. . Laryngoscope 117:, 210–214. [CrossRef] [PubMed]
    [Google Scholar]
  132. Shin E. J. , Chang J. I. , Choi B. , Wanna G. , Ebert O. , Genden E. M. , Woo S. L. . ( 2007b; ). Fusogenic vesicular stomatitis virus for the treatment of head and neck squamous carcinomas. . Otolaryngol Head Neck Surg 136:, 811–817. [CrossRef] [PubMed]
    [Google Scholar]
  133. Shinozaki K. , Ebert O. , Suriawinata A. , Thung S. N. , Woo S. L. . ( 2005; ). Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats. . J Virol 79:, 13705–13713. [CrossRef] [PubMed]
    [Google Scholar]
  134. Staeheli P. , Pavlovic J. . ( 1991; ). Inhibition of vesicular stomatitis virus mRNA synthesis by human MxA protein. . J Virol 65:, 4498–4501.[PubMed]
    [Google Scholar]
  135. Stanifer M. L. , Cureton D. K. , Whelan S. P. . ( 2011; ). A recombinant vesicular stomatitis virus bearing a lethal mutation in the glycoprotein gene uncovers a second site suppressor that restores fusion. . J Virol 85:, 8105–8115. [CrossRef] [PubMed]
    [Google Scholar]
  136. Stephenson K. B. , Barra N. G. , Davies E. , Ashkar A. A. , Lichty B. D. . ( 2012; ). Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity. . Cancer Gene Ther 19:, 238–246. [CrossRef] [PubMed]
    [Google Scholar]
  137. Stojdl D. F. , Lichty B. , Knowles S. , Marius R. , Atkins H. , Sonenberg N. , Bell J. C. . ( 2000; ). Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. . Nat Med 6:, 821–825. [CrossRef] [PubMed]
    [Google Scholar]
  138. Stojdl D. F. , Lichty B. D. , tenOever B. R. , Paterson J. M. , Power A. T. , Knowles S. , Marius R. , Reynard J. , Poliquin L. . & other authors ( 2003; ). VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. . Cancer Cell 4:, 263–275. [CrossRef] [PubMed]
    [Google Scholar]
  139. Sun W. H. , Pabon C. , Alsayed Y. , Huang P. P. , Jandeska S. , Uddin S. , Platanias L. C. , Rosen S. T. . ( 1998; ). Interferon-α resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. . Blood 91:, 570–576.[PubMed]
    [Google Scholar]
  140. Tumilasci V. F. , Olière S. , Nguyên T. L. , Shamy A. , Bell J. , Hiscott J. . ( 2008; ). Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis. . J Virol 82:, 8487–8499. [CrossRef] [PubMed]
    [Google Scholar]
  141. van den Pol A. N. , Dalton K. P. , Rose J. K. . ( 2002; ). Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein. . J Virol 76:, 1309–1327. [CrossRef] [PubMed]
    [Google Scholar]
  142. Wang B. X. , Rahbar R. , Fish E. N. . ( 2011; ). Interferon: current status and future prospects in cancer therapy. . J Interferon Cytokine Res 31:, 545–552. [CrossRef] [PubMed]
    [Google Scholar]
  143. Weidner J. M. , Jiang D. , Pan X. B. , Chang J. , Block T. M. , Guo J. T. . ( 2010; ). Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. . J Virol 84:, 12646–12657. [CrossRef] [PubMed]
    [Google Scholar]
  144. Whelan S. P. , Ball L. A. , Barr J. N. , Wertz G. T. . ( 1995; ). Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. . Proc Natl Acad Sci U S A 92:, 8388–8392. [CrossRef] [PubMed]
    [Google Scholar]
  145. Whitlow Z. W. , Connor J. H. , Lyles D. S. . ( 2006; ). Preferential translation of vesicular stomatitis virus mRNAs is conferred by transcription from the viral genome. . J Virol 80:, 11733–11742. [CrossRef] [PubMed]
    [Google Scholar]
  146. Whitlow Z. W. , Connor J. H. , Lyles D. S. . ( 2008; ). New mRNAs are preferentially translated during vesicular stomatitis virus infection. . J Virol 82:, 2286–2294. [CrossRef] [PubMed]
    [Google Scholar]
  147. Willmon C. , Diaz R. M. , Wongthida P. , Galivo F. , Kottke T. , Thompson J. , Albelda S. , Harrington K. , Melcher A. , Vile R. . ( 2011; ). Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide. . Mol Ther 19:, 140–149. [CrossRef] [PubMed]
    [Google Scholar]
  148. Wollmann G. , Tattersall P. , van den Pol A. N. . ( 2005; ). Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential. . J Virol 79:, 6005–6022. [CrossRef] [PubMed]
    [Google Scholar]
  149. Wollmann G. , Rogulin V. , Simon I. , Rose J. K. , van den Pol A. N. . ( 2010; ). Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells. . J Virol 84:, 1563–1573. [CrossRef] [PubMed]
    [Google Scholar]
  150. Wong L. H. , Krauer K. G. , Hatzinisiriou I. , Estcourt M. J. , Hersey P. , Tam N. D. , Edmondson S. , Devenish R. J. , Ralph S. J. . ( 1997; ). Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3γ. . J Biol Chem 272:, 28779–28785. [CrossRef] [PubMed]
    [Google Scholar]
  151. Wongthida P. , Diaz R. M. , Galivo F. , Kottke T. , Thompson J. , Pulido J. , Pavelko K. , Pease L. , Melcher A. , Vile R. . ( 2010; ). Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. . Cancer Res 70:, 4539–4549. [CrossRef] [PubMed]
    [Google Scholar]
  152. Wongthida P. , Diaz R. M. , Galivo F. , Kottke T. , Thompson J. , Melcher A. , Vile R. . ( 2011a; ). VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling. . Mol Ther 19:, 150–158. [CrossRef] [PubMed]
    [Google Scholar]
  153. Wongthida P. , Diaz R. M. , Pulido C. , Rommelfanger D. , Galivo F. , Kaluza K. , Kottke T. , Thompson J. , Melcher A. , Vile R. . ( 2011b; ). Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. . Hum Gene Ther 22:, 1343–1353. [CrossRef] [PubMed]
    [Google Scholar]
  154. Wu L. , Huang T. G. , Meseck M. , Altomonte J. , Ebert O. , Shinozaki K. , García-Sastre A. , Fallon J. , Mandeli J. , Woo S. L. . ( 2008; ). rVSV(MΔ51)-M3 is an effective and safe oncolytic virus for cancer therapy. . Hum Gene Ther 19:, 635–647. [CrossRef] [PubMed]
    [Google Scholar]
  155. Yuan H. , Puckett S. , Lyles D. S. . ( 2001; ). Inhibition of host transcription by vesicular stomatitis virus involves a novel mechanism that is independent of phosphorylation of TATA-binding protein (TBP) or association of TBP with TBP-associated factor subunits. . J Virol 75:, 4453–4458. [CrossRef] [PubMed]
    [Google Scholar]
  156. Zhang K. X. , Matsui Y. , Hadaschik B. A. , Lee C. , Jia W. , Bell J. C. , Fazli L. , So A. I. , Rennie P. S. . ( 2010; ). Down-regulation of type I interferon receptor sensitizes bladder cancer cells to vesicular stomatitis virus-induced cell death. . Int J Cancer 127:, 830–838.[PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.046672-0
Loading
/content/journal/jgv/10.1099/vir.0.046672-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error